SESSION TITLE: Lung Cancer III
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: To evaluate the efficiency and safety of PARP inhibitors in cancer therapy.
METHODS: We carried out a comprehensive search to identify potential articles in PUBMED and EMBASE up to January 2015, using the search terms: “PARP inhibitors” or “Olaparib” or “Iniparib” or “Veliparib” or “Rucaparib” or “Niraparib” or “Talazoparib” and “cancer” or “tumor” or “carcinoma”, limited to clinical trials. The hazard ratio (HR) of the median OS and median PFS with 95% confidence intervals (CIs), and adverse events were extracted from most of the trials to carry out the meta analysis.